Skip to main content

First Patient Enrolled in New Sub-study in Ovarian Cancer Immunotherapy Platform Trial

Expansion of the IPROC platform study introduces a new immunotherapy combination and patient population, accelerating progress toward more effective ovarian cancer treatments
enrollment of the first patient in the third substudy IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC)

The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) announced the enrollment of the first patient in the third substudy IND240C of their ongoing Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC).

The IND240C (IPROC)trial is a phase 2, multi-center, platform study designed to test novel immunotherapy combinations for high-grade serous ovarian cancer, an aggressive subtype that has poor prognoses and limited therapeutic options.

Platform trials employ a master protocol that enables the efficient evaluation of multiple treatment combinations within a single, adaptive framework. Each new cohort functions as a distinct, independent trial—allowing researchers to rapidly introduce and test promising therapies in targeted patient populations. 

Building on the first two substudies (A and B)—which evaluated a PD-L1 inhibitor in combination with two distinct antibody-drug conjugates (ADCs)—Cohort C marks a significant expansion of the IPROC study. This new sub-study introduces both a new therapeutic combination and a broader patient population. For the first time in this trial, patients with clear cell ovarian cancer, an aggressive subtype, will be enrolled alongside patients with high-grade serous ovarian cancer.

Substudy C will evaluate the combination of toripalimab, a PD-1 inhibitor, and ENB-003, a first-in-class endothelin B receptor inhibitor that targets pathways implicated in tumor growth and immune suppression. The substudy will begin with 20 patients—10 with clear cell and 10 with high-grade serous disease—with the potential for expansion based on clinical outcomes.

Funded by CRI and the Ovarian Cancer Research Alliance (OCRA) and sponsored by CCTG, with support from the Canadian Cancer Society, this study represents a global effort to accelerate immunotherapy discovery for women facing one of the most difficult-to-treat cancers.

The enrollment of the first patient in substudy C marks an exciting milestone for the IPROC study and for the broader effort to bring transformative immunotherapies to patients who need them most. This expansion reflects CRI’s unwavering commitment to building a world immune to cancer.

About the IPROC Platform Trial

The IPROC clinical trial uses an adaptive platform study design that utilizes a single master protocol to evaluate multiple immunotherapy combinations. This allows multiple treatments to be evaluated in different groups of patients, or cohorts, from the same patient population. Such a study design offers flexibility in that different treatments can be evaluated in different cohorts, treatment regimens can be modified between cohorts, and treatment selection criteria can be customized for a specific cohort. The trial, titled Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) has two ongoing cohorts.